Almagel A, 170 ml suspension

Pharmacotherapeutic group

Antacid + local anesthetic

ATX code: A02AB10

Pharmacological properties

.Pharmacodynamics

Almagel^® A is a drug that is a balanced combination of algeldrate (aluminum hydroxide), magnesium hydroxide and benzocaine. Almagel^® A neutralizes free hydrochloric acid in the stomach, reduces the activity of pepsin, which leads to a decrease in the digestive activity of gastric juice. It has a coating and adsorptive effect. Protects the mucous lining of the stomach by stimulating the synthesis of prostaglandins (cytoprotective effect).

It protects the mucous membrane from inflammatory and erosive-hemorrhagic lesions due to irritating and ulcerogenic agents such as ethyl alcohol and non-steroidal anti-inflammatory drugs (e.g., indomethacin, diclofenac, aspirin, acetylsalicylic acid, corticosteroid drugs). The therapeutic effect after taking the drug comes in 3-5 minutes. The duration of action depends on the rate of gastric emptying.

If taken on an empty stomach, the effect lasts up to 60 minutes. When taken one hour after a meal, the antacid action may last up to 3 hours.

Does not cause secondary hypersecretion of gastric juice.

Benzocaine has a local analgesic effect in the presence of severe pain syndrome.

Pharmacokinetics

Algeldrate

absorption –small amounts of the drug are resorbed with little or no change in the concentration of aluminum salts in the blood.

Distribution – no.

Metabolism – no.

Evolution – excreted through the intestine.

Magnesium hydroxide

absorption – magnesium ions are resorbed in about 10% of the dose taken and do not change the concentration of magnesium ions in the blood.

Distribution – is usually local.

Metabolism – no.

Evolution – is excreted through the intestine.

Benzocaine

Benzocaine is absorbed in minimal amounts and has virtually no systemic effects on the body. Its local analgesic effect occurs 1-2 minutes after taking the suspension.

Indications

Active ingredient

Composition

5 ml (1 scoop) of suspension contain: acting ingredients: aluminum hydroxide gel 2.18 g (in terms of Al2O3 218 mg), magnesium hydroxide paste 350 mg (in terms of MgO 75 mg), benzocaine 109 mg; excipients: Hydrogen peroxide solution 30% 0.41 mg, sorbitol 801.15 mg, guetellose 15.26 mg, methyl parahydroxybenzoate 10.90 mg, propyl parahydroxybenzoate 1.363 mg, butyl parahydroxybenzoate 1,363 mg, sodium saccharinate dihydrate 0.818 mg, propylene glycol 327.00 mg, macrogol 4000 218.00 mg, lemon oil 1.635 mg, ethanol 96% 98.10 mg, purified water to 5 ml.

10 ml (1 sachet) of suspension contain: acting ingredients: aluminum hydroxide gel 4.36 g (in terms of Al2O3 436 mg), magnesium hydroxide paste 700 mg (in terms of MgO 150 mg), benzocaine 218 mg; excipients: Hydrogen peroxide solution 30% 0.82 mg, sorbitol 1602.30 mg, guetellose 30.52 mg, methyl parahydroxybenzoate 21.80 mg, propyl parahydroxybenzoate 2.726 mg, butyl parahydroxybenzoate 2,726 mg, sodium saccharinate dihydrate 1.636 mg, propylene glycol 654.00 mg, macrogol 4000 436.00 mg, lemon oil 3.27 mg, ethanol 96% 196.20 mg, purified water to 10 ml.

How to take, the dosage

For oral administration.

Adults

5-10 ml (1-2 scoops or 1 sachet) 3-4 times a day 10-15 minutes before meals.

The maximum duration of treatment is 7 days, then the drug Almagel® is changed to treatment.

It is not recommended to take liquids for 15 minutes after taking the drug.

The suspension must be thoroughly homogenized before use by shaking the bottle or by kneading and shaking the bag.

Interaction

Special Instructions

Synopsis

Contraindications

Side effects

Unwanted reactions are listed according to the system-organ class of the Medical Dictionary of Regulatory Affairs (MedDRA). Unwanted reactions are categorized according to the World Health Organization (WHO) classification: very common (≥1/10); common (≥1/100, < 1/10); infrequent (≥1/1000, < 1/100); rare (≥1/10000, < 1/1000); very rare (< 1/10000); frequency unknown (cannot be determined based on available data).

Immune system disorders:frequency unknown-allergic reactions such as bronchospasm, pruritus, urticaria, angioedema, and anaphylactic reactions of the rapid type.

Disorders of metabolism and nutrition: very rare – hypermagnesemia1; frequency unknown – hyperaluminemia, hypophosphatemia2, which may lead to increased bone resorption, hypercalciuria, osteomalacia (see See section “Special Indications”).

Gastrointestinal tract disorders: infrequent – diarrhea or constipation; frequency unknown – abdominal pain.

1Anomalies have been observed with prolonged use of magnesium hydroxide in patients with renal insufficiency.

2Was observed with prolonged use of high doses, and with usual doses in patients with limited phosphate intake.

Overdose

In a single overdose there are no other signs of overdose other than constipation, flatulence, and a sensation of metallic taste.

In prolonged use of high doses nephrocalcinosis, the appearance of severe constipation, mild drowsiness, hypermagnesemia are possible. There may also be signs of metabolic alkalosis: changes in mood or mental alertness, numbness or pain in the muscles, irritability and rapid fatigue, slowed breathing, unpleasant taste sensations.

It is necessary to take immediate measures to quickly eliminate the medication from the body by gastric lavage (induction of vomiting, taking activated charcoal).

Pregnancy use